期刊
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
卷 11, 期 1, 页码 6-14出版社
SPRINGER
DOI: 10.1007/s11910-010-0162-y
关键词
Stroke; TIA; Antiplatelet; Prevention; Aspirin; Clopidogrel; Dipyridamole; Warfarin; Trial; Aspirin failure; Clopidogrel resistance; Cardioembolic
资金
- NIH
- NINDS
Stroke is one of the leading causes of disability; most are due to atherothrombotic mechanisms. About one third of ischemic strokes are preceded by other stroke or transient ischemic attacks. Stroke survivors are at high risk for vascular events (i.e., cerebrovascular and cardiovascular). Prevention of recurrent stroke and other major vascular events can be accomplished by control of risk factors. Nonetheless, the use of antiplatelet agents remains the fundamental component of secondary stroke prevention strategy in patients with noncardioembolic disease. Currently, the uses of aspirin, clopidogrel, or aspirin plus extended-release dipyridamole are valid alternatives for stroke or transient ischemic attack patients. To maximize the beneficial effects of these agents, the treatment should be initiated as early as possible and continue on a lifelong basis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据